SMMT vs. ELAN, INSM, ROIV, ASND, LEGN, CERE, VKTX, ITCI, JAZZ, and BPMC
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Elanco Animal Health (NYSE:ELAN) and Summit Therapeutics (NASDAQ:SMMT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.
Elanco Animal Health has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500.
In the previous week, Elanco Animal Health and Elanco Animal Health both had 16 articles in the media. Summit Therapeutics' average media sentiment score of 0.86 beat Elanco Animal Health's score of 0.60 indicating that Elanco Animal Health is being referred to more favorably in the media.
Summit Therapeutics received 155 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 57.09% of users gave Summit Therapeutics an outperform vote while only 54.13% of users gave Elanco Animal Health an outperform vote.
Elanco Animal Health presently has a consensus price target of $18.29, suggesting a potential upside of 3.43%. Summit Therapeutics has a consensus price target of $10.50, suggesting a potential upside of 20.90%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Elanco Animal Health.
Summit Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Summit Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics has a net margin of 0.00% compared to Summit Therapeutics' net margin of -29.83%. Summit Therapeutics' return on equity of 5.98% beat Elanco Animal Health's return on equity.
97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Summit Therapeutics beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
